Ganetespib radiosensitization for liver cancer therapy

scientific article published on 16 March 2016

Ganetespib radiosensitization for liver cancer therapy is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1080/15384047.2016.1156258
P932PMC publication ID4910914
P698PubMed publication ID26980196

P50authorYoshinori KatoQ44454669
Phuoc T. TranQ55459004
Kekoa TaparraQ57618681
Michael LimQ87792919
Hailun WangQ89307804
P2093author name stringJoseph M Herman
Jessica A Cades
Robert A Anders
David Proia
Anvesh Annadanam
Katriana M Nugent
Matthew Ballew
Reem Malek
Sarah Manmiller
Sivarajan T Chettiar
Zineb Belcaid
P2860cites workPathogenesis of hepatocellular carcinoma and molecular therapies.Q37456002
STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer.Q37820497
Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiationQ38247880
Overexpressed-eIF3I interacted and activated oncogenic Akt1 is a theranostic target in human hepatocellular carcinomaQ39185396
Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.Q39203018
Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapyQ39432501
Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiationQ40600964
Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitizationQ40632085
Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.Q44705946
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancerQ46518366
Mean inactivation dose: a useful concept for intercomparison of human cell survival curvesQ71405944
A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinomaQ85364824
How grim is hepatocellular carcinoma?Q27001669
Sorafenib in advanced hepatocellular carcinomaQ27861075
Multidrug resistance in cancer: role of ATP-dependent transportersQ28208049
The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transitionQ28301955
The primary structure of MEK, a protein kinase that phosphorylates the ERK gene productQ28316871
Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signalingQ28741023
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialQ29547903
Principles of cancer therapy: oncogene and non-oncogene addictionQ29616779
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002Q29619974
Survival and death signals can predict tumor response to therapy after oncogene inactivationQ30574736
Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancerQ33836330
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancerQ33912171
Hepatocellular carcinoma radiation therapy: review of evidence and future opportunitiesQ34646117
Inhibition of HSP90 molecular chaperones: moving into the clinicQ34654791
Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinomaQ34770140
Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.Q35360310
Clusterin facilitates metastasis by EIF3I/Akt/MMP13 signaling in hepatocellular carcinomaQ35550129
The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma CellsQ35818450
Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.Q36336795
Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancerQ36347106
Genetics of hepatocellular tumors.Q36519006
Sorafenib for treatment of hepatocellular carcinoma: a systematic reviewQ36680204
Genomics and signaling pathways in hepatocellular carcinoma.Q36733952
High-resolution, small animal radiation research platform with x-ray tomographic guidance capabilitiesQ37020792
Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.Q37157400
HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repairQ37163368
The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancerQ37235527
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinomaQ37284612
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancerQ37417712
P275copyright licenseCreative Commons Attribution-NonCommercial 3.0 UnportedQ18810331
P6216copyright statuscopyrightedQ50423863
P433issue4
P921main subjectliver cancerQ623031
P304page(s)457-466
P577publication date2016-03-16
P1433published inCancer Biology and TherapyQ2544651
P1476titleGanetespib radiosensitization for liver cancer therapy
P478volume17

Reverse relations

cites work (P2860)
Q47102428Boosting the effects of hyperthermia-based anticancer treatments by HSP90 inhibition
Q64266721Evaluation of the Radiosensitizing Potency of Bromelain for Radiation Therapy of 4T1 Breast Cancer Cells
Q42364239The Biology of Aging and Cancer: A Brief Overview of Shared and Divergent Molecular Hallmarks

Search more.